Reclassification of clinical exome data leads to significant clinical assessment changes in almost half of the patients
Öz
Purpose: With the global accumulation of genetic/clinical data, we are understanding the clinical significance of the reclassification of pathogenicity for gene variants. We hypothesized that this evolution in classification(s) may cause clinically-relevant discrepancies in the genetic risk assessment of subjects. In this study, we sought to reclassify the clinical exome sequence (CES) data of our patients to assess whether these changes would have clinical significance.
Materials and Methods: The study included CES data of 23 cases diagnosed with cancer or familial cancer predisposition. The variants were first classified in 2020 and then reclassified a year after based on the ACMG database. Chart reviews were performed to record clinical history and interventions.
Results: In the first classification of CES data, a total of 80 variants were identified as being not benign (26 likely pathogenic/pathogenic and 54 variants of undetermined significance (VUS)). The clinical significance of fifteen variants (19%) changed after reclassification in 10 patients (43%). The only upgraded variant was the c.9097 dup in exon 23 of BRCA2 gene (likely pathogenic to pathogenic). Fourteen variants were downgraded at reanalysis in 9 patients: from pathogenic to likely pathogenic (2 variants), pathogenic to VUS (2), likely pathogenic to VUS (4), and VUS to benign (6).
Conclusion: Considering that the clinical significance of CES data changed due to reclassification in almost half of the studied patients, we believe genetic variant-related data should be assessed at regular intervals, regardless of follow-up status in the clinic.
Anahtar Kelimeler
cancer, clinical exome sequencing, likely pathogenic/pathogenic variants
Proje Numarası
KA21/303
Teşekkür
All authors contributed to the study’s conception and design. The first draft of the manuscript was written by Umut Arda Bayraktar, Feride Iffet Sahin, Yunus Kazım Terzi and all authors commented on previous versions of the manuscript. All authors read and approve the final manuscript.
Kaynakça
- Hood L, Galas D. The digital code of DNA . Nature. 2003;421:444-8.
- Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature. 1982;300:149-52.
- Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-99.
- Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD et al. Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium. Am J Hum Genet. 2016;98:1067-76.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24.
- Rivera-Muñoz EA, Milko LV, Harrison SM, Azzariti DR, Kurtz CL, Lee K et al. ClinGen variant curation expert panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation. Hum Mutat. 2018;39:1614-22.
- Ji J, Leung ML, Baker S, Deignan JL, Santani A. Clinical exome reanalysis: Current practice and beyond. Mol Diagn Ther. 2021;25:529-36.
- Al-Nabhani M, Al-Rashdi S, Al-Murshedi F, Al-Kindi A, Al-Thihli K, Al-Saegh A et al. Reanalysis of exome sequencing data of intellectual disability samples: Yields and benefits. Clin Genet. 2018;94:495-501.
- Felicio PS, Grasel RS, Campacci N, de Paula AE, Galvao HCR, Torrezan GT et al. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer. Hum Mutat. 2021;42:290-9.
- Susswein LR, Marshall ML, Nusbaum R, Postula KJV, Weissman SM, Yackowski L et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet.Med. 2016;18:823-32.
